Is limb lengthening surgery safe in 2026?

The any-complication figure is broad on purpose. Pin-site irritation in external-fixator patients counts. Transient calf tingling in a PRECICE 2 patient who walked too soon counts. A 3-degree loss of knee flexion at month 6 counts. JOSR 2025 grouped these as Grade I and Grade II events on the Caton-Pannier scale and found they accounted for roughly two-thirds of all reported complications.

The Grade III and Grade IV events are where outcomes change. Those are non-union, permanent nerve injury, deep infection, vascular injury, and refracture. The serious band sits at 5-15% across cosmetic series. JOSR 2025 reported 5.1% delayed union, 3.2% nerve compression, and 2.4% deep infection pooled across methods. The 2021 Acta Orthopaedica review of 983 PRECICE and FITBONE segments (PMC7919879) reported a lower serious-event rate, 4.8%, which is consistent with internal-nail series tracking below the all-method average.

Reading a clinic's complication rate without the grading scale is meaningless. A clinic that reports 8% may be counting only Grade III-IV events. A clinic that reports 35% may be counting every pin-site dressing change. The denominator matters more than the percentage.

Method choice changes the complication profile but not as dramatically as patients assume. Internal nails are the safest category in cosmetic indication. Hybrid LON sits in the middle. Pure external-fixator Ilizarov sits at the high end and is now mostly reserved for reconstructive cases.

The ranges below are pulled from our method spec library, cross-checked against pooled rates in the JOSR 2025 review and the FITBONE/PRECICE Acta Orthopaedica 2021 paper. They describe cosmetic indication only, reconstructive cases (limb-length discrepancy, dwarfism, post-trauma) trend higher across every method because the patients are older or sicker.

Four events dominate the serious-complication band. Each one can change the timeline by 3-12 months, cost an extra $5,000-$25,000 to treat, and in a small share of cases never fully resolves.

Non-union is the most common. The new bone fails to harden on schedule, and the surgeon either dynamises the implant, adds bone graft, or both. JOSR 2025 puts the pooled rate at 5.1%. Internal-nail series cluster at 2-4%; LON and Ilizarov series cluster at 6-8%. Smoking, distraction faster than 1 mm/day, low vitamin D, and patient age above 45 are the documented risk factors.

Nerve injury is the second most common. The peripheral nerves stretch alongside the bone, most tolerate it, some do not. Tibial lengthening carries the higher risk because the peroneal nerve sits in a tight osseofascial tunnel below the knee. JOSR 2025 reported 3.2% nerve compression pooled. About 80% of these are transient and resolve over 3-9 months. The remaining 20% leave persistent foot drop, sensory loss, or chronic neuropathic pain. Slower distraction (0.75 mm/day) and prophylactic peroneal decompression are the documented risk-reduction levers, surgeon experience matters more here than method.

Deep infection is the third. Superficial pin-site infections affect 20-40% of external-fixator patients during distraction and clear with oral antibiotics. Deep infection, osteomyelitis or implant-tract sepsis, is a different category. Internal-nail series report 1-2%. LON and Ilizarov series report 3-4% because the pin-bone interface creates a permanent contamination route for the entire fixator period. Treatment is implant removal, 6-12 weeks of IV antibiotics, then reimplantation if the patient still wants to finish lengthening.

Refracture is the fourth and the most patient-driven. The new bone is fragile through consolidation, which runs 3-6 months past the end of distraction. Patients who return to running, basketball, or even aggressive walking at 6-9 months instead of 12+ months account for the disproportionate share of refractures in case-series follow-up. PRECICE patients have a false sense of recovery because there is no visible external hardware. The bone is still half-formed. Avoidable in roughly 90% of cases by following the surgeon's return-to-sport protocol.

The single most actionable number in the safety literature is not in any method spec sheet. It is in the surgeon's annual case count. High-volume surgeons (more than 50 cosmetic lengthening cases per year) report serious-complication rates clustering around 5%. Low-volume surgeons (fewer than 10 cases per year) report rates that can exceed 15%. The 3x gap between high and low volume is wider than the gap between any two methods.

This is not a small variable. Choosing a high-volume surgeon doing LON is statistically safer than choosing a low-volume surgeon doing PRECICE, the cleaner method does not rescue a learning curve. Volume is also country-agnostic. The Turkish surgeon doing 200 cases a year is statistically safer than the American doing 40.

A handful of surgeons in our directory publish their case volumes openly. Dr. Dror Paley at the Paley Institute in West Palm Beach has performed limb lengthening since 1986, with patient flow from 90+ countries, the highest cumulative volume of any active limb-lengthening surgeon in the world. Prof. Yasser Elbatrawy at the Cairo International Centre for Limb Lengthening reports 4,000+ lengthening procedures since 1996 and 400+ specifically cosmetic since 2002. Dr. S. Robert Rozbruch directs the Limb Lengthening Service at Hospital for Special Surgery in New York, with a mixed reconstructive and cosmetic caseload that runs into the hundreds annually.

In Istanbul, the global volume capital for LON, Dr. Halil Buldu at LiveLifeTaller and Prof. Dr. Yuksel Yurttas both report 100+ cosmetic cases per year. Dr. Shahab Mahboubian at LimbplastX in Las Vegas reports comparable volume on PRECICE-focused practice. These are the surgeons whose published outcomes anchor the low end of the serious-complication band.

Most published complication rates pool cosmetic and reconstructive indications. That overstates the cosmetic risk because reconstructive patients are older, sicker, or carrying complex deformity that adds intrinsic risk. Cosmetic-only series, patients who are otherwise healthy adults seeking stature gain, trend a few percentage points below the pooled headline.

Cosmetic-specific rates run roughly 25-35% any-complication and 3-8% serious. Reconstructive series trend 35-50% any-complication and 8-15% serious. The 2018 EFAS series of cosmetic-only PRECICE patients reported a 12% any-complication rate and 1.8% serious, among the best published numbers anywhere, and from a single high-volume surgeon, which underlines the volume effect.

Reading any claim of complication rate, ask which population it refers to. A clinic quoting 5% serious complications for cosmetic LL is in the credible range. A clinic quoting 1% serious complications without qualifying the indication, the grading scale, or the denominator is over-claiming. Cross-check against published series before you take a clinic's word for its own number.

The PRECICE Stryde nail received an FDA Class I recall in April 2021 after reports of corrosion at the telescoping junction and associated bone changes (osteolysis). NuVasive Specialized Orthopedics, now Globus Medical, since the September 2023 merger, paused US distribution and the recall remains active. Stryde is no longer implanted at any clinic in our directory as of 2026.

This is its own story and deserves its own page. We covered the timeline, the patient-monitoring protocol, and what to do if a clinic in 2026 still lists Stryde on its method menu in our dedicated explainer. Read that one for the detail, this article focuses on the larger safety picture beyond Stryde. The recall was a meaningful single-implant event but did not change the underlying safety profile of the PRECICE platform overall. PRECICE 2 and PRECICE Max remain in current use with the safety profile described above.

The questions below separate clinics that own their data from clinics that hope you do not ask. None require medical training to evaluate the answer.

First: how many cosmetic-indication lengthening cases did the lead surgeon perform in the last calendar year? A surgeon under 30 is low-volume by the literature. Over 75 is high-volume.

Second: what is your published any-complication rate, and what is your published serious-complication rate? A clinic that cannot separate the two has not measured them on the Caton-Pannier or comparable grading scale.

Third: how many revision surgeries did the lead surgeon perform on their own cases last year? Hidden revision counts are the easiest way to suppress a complication number.

Fourth: what is the published rate of permanent, not transient, nerve injury? The transient-versus-permanent distinction is the line between proper follow-up and hope.

Fifth: will you share an anonymised list of complications from the last 24 months? A clinic that says yes is in a different category from a clinic that says no. Patients we have spoken with report that the Paley Institute, HSS, and Acibadem Healthcare Group will share anonymised data on request. Most clinics will not. Treat the refusal as data.

Limb lengthening surgery in 2026 is safer than it was at any point in the last four decades. The internal-nail platform (PRECICE 2 and PRECICE Max) is mature, the surgical technique is standardised, and the high-volume centers publish outcomes that bear comparison with major joint replacement surgery, which carries a comparable any-complication rate in the 15-20% range.

The risk is real but quantifiable. A serious complication that changes the timeline, costs extra, or in a small share of cases never fully resolves affects 5-15% of patients depending on method and surgeon. A motivated, healthy adult who picks a high-volume surgeon and follows the recovery timeline lands at the low end of that band. A patient who chooses on price alone, who skips physiotherapy, or who returns to impact sport at month 6 lands somewhere closer to the high end.

The answer to the title question is not yes or no. It is conditional. Limb lengthening is safe enough to undergo if, and only if, three things are true. The surgeon has published case volume above 50 cosmetic cases per year. The clinic owns its complication data and will discuss it on the record. The patient is willing to spend 9-18 months following a recovery protocol they do not get to negotiate. Patients who can answer yes to all three are looking at a 95% probability of a successful outcome. Patients who cannot are looking at a different number entirely.